Last checked at 25 Apr 2024 14:27
Tissue Regenix Group plc
('Tissue Regenix', the 'Group', or the 'Company')
Result of Annual General Meeting
Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that at the Annual General Meeting ('AGM') held earlier today, all resolutions were duly passed on a show of hands.
The results of the proxy votes received in respect of the resolutions, given to the Chair prior to the meeting, are set out below:
Resolution | In favour | % | Against | % | Withheld | |
1 | Ordinary | 30,257,029 | 99.99 | 610 | 0.01 | 12,274 |
2 | Ordinary | 30,249,468 | 99.98 | 7,296 | 0.02 | 13,149 |
3 | Ordinary | 30,254,468 | 99.99 | 2,296 | 0.01 | 13,149 |
4 | Ordinary | 30,254,468 | 99.99 | 2,296 | 0.01 | 13,149 |
5 | Ordinary | 30,254,968 | 99.99 | 1,796 | 0.01 | 13,149 |
6 | Ordinary | 30,254,468 | 99.99 | 2,296 | 0.01 | 13,149 |
7 | Ordinary | 30,254,468 | 99.99 | 2,296 | 0.01 | 13,149 |
8 | Ordinary | 30,255,203 | 99.99 | 1,561 | 0.01 | 13,149 |
9 | Ordinary | 30,255,203 | 99.99 | 2,436 | 0.01 | 12,274 |
10 | Ordinary | 30,253,968 | 99.96 | 11,671 | 0.04 | 4,274 |
11 | Special | 30,049,183 | 99.28 | 216,456 | 0.71 | 4,274 |
12 | Special | 30,236,441 | 99.93 | 21,198 | 0.07 | 12,274 |
Notes:
1. A "Vote withheld" is not counted in the calculation of the percentage of shares voted "In favour" or "Against".
2. As at 23 April 2023, being the voting deadline date in respect of the Annual General Meeting, the total number of Ordinary Shares of 0.1p each in issue and the total number of voting rights was 70,574,468.
The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 19 March 2024.
For more information:
Tissue Regenix Group plc | www.tissueregenix.com | |
David Cocke, Chief Financial Officer | via Walbrook PR | |
Cavendish Capital Markets Limited (Nominated Adviser and Broker) | ||
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance | ||
Nigel Birks/Harriet Ward - ECM | ||
| ||
Walbrook PR (Financial PR and IR) | Tel: +44 (0)20 7933 8780 | |
Alice Woodings/Charlotte Edgar | TissueRegenix@walbrookpr.com | |
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.